Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire•26/10/2026•09:30 ET
0
Key Highlights
- ➤Coherus will release third quarter 2026 financial results November 9, 2026
- ➤Management will host a conference call and webcast at 5:00 p.m. EDT
- ➤LOQTORZI is Coherus’ approved next-generation PD-1 inhibitor
- ➤Tagmokitug is in Phase 1b/2a studies for advanced solid tumors
- ➤Casdozokitug is in a Phase 2 first-line hepatocellular carcinoma study
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Get started
Create a free account to read the full story.